MX342324B - Formulaciones de otamixaban con estabilidad mejorada. - Google Patents

Formulaciones de otamixaban con estabilidad mejorada.

Info

Publication number
MX342324B
MX342324B MX2013011260A MX2013011260A MX342324B MX 342324 B MX342324 B MX 342324B MX 2013011260 A MX2013011260 A MX 2013011260A MX 2013011260 A MX2013011260 A MX 2013011260A MX 342324 B MX342324 B MX 342324B
Authority
MX
Mexico
Prior art keywords
otamixaban
formulations
improved stability
amino
methyl
Prior art date
Application number
MX2013011260A
Other languages
English (en)
Other versions
MX2013011260A (es
Inventor
Kamm Walter
Bussemer Till
Andert Doris
Kühn Bernd
Todt Ernst-Josef
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2013011260A publication Critical patent/MX2013011260A/es
Publication of MX342324B publication Critical patent/MX342324B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

La invención se refiere a una composición farmacéutica que comprende (2R.3R)-2-{3-[amino(imino)metil]bencil}-3-{[4-(1-oxidopi ridin-4-il)benzoil]amino}butanoato de metilo o una sal farmacéuticamente aceptable del mismo y un compuesto reactivo ácido farmacéuticamente aceptable, o a una solución o dispersión acuosa de la composición así como a un procedimiento para la preparación de la misma, a métodos para usar tales composiciones para tratar a sujetos que sufren enfermedades que se pueden mejorar por la administración de un inhibidor del Factor Xa.
MX2013011260A 2011-03-29 2012-03-27 Formulaciones de otamixaban con estabilidad mejorada. MX342324B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11305347 2011-03-29
US201161499941P 2011-06-22 2011-06-22
PCT/EP2012/055361 WO2012130819A1 (en) 2011-03-29 2012-03-27 Otamixaban formulations with improved stability

Publications (2)

Publication Number Publication Date
MX2013011260A MX2013011260A (es) 2014-03-27
MX342324B true MX342324B (es) 2016-09-23

Family

ID=44584895

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011260A MX342324B (es) 2011-03-29 2012-03-27 Formulaciones de otamixaban con estabilidad mejorada.

Country Status (18)

Country Link
US (3) US20120252852A1 (es)
EP (1) EP2691075A1 (es)
JP (1) JP5993933B2 (es)
KR (1) KR101844623B1 (es)
CN (1) CN103561723B (es)
AR (1) AR085580A1 (es)
AU (1) AU2012234323A1 (es)
BR (1) BR112013024801A2 (es)
CA (1) CA2830962C (es)
CO (1) CO6801755A2 (es)
EA (1) EA025572B1 (es)
IL (1) IL228573A (es)
MA (1) MA35050B1 (es)
MX (1) MX342324B (es)
SG (1) SG193932A1 (es)
UY (1) UY33975A (es)
WO (1) WO2012130819A1 (es)
ZA (1) ZA201308061B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342324B (es) 2011-03-29 2016-09-23 Sanofi Sa Formulaciones de otamixaban con estabilidad mejorada.
NZ750187A (en) 2013-01-31 2020-09-25 Vertex Pharma Pyridone amides as modulators of sodium channels
DE102013212933B3 (de) * 2013-07-03 2014-11-27 Schaeffler Technologies Gmbh & Co. Kg Lageranordnung in einem Elektromotor
DK3668516T3 (da) 2017-08-16 2021-12-13 Merck Patent Gmbh Stabile lyofilisater omfattende 5,10-methylen-(6r)-tetrahydrofolsyre og en dicarboxylsyre
CN109010273B (zh) * 2018-10-08 2021-03-19 中国药科大学 一种阿哌沙班纳米混悬剂及其制备方法
CN113384526A (zh) * 2021-08-03 2021-09-14 合肥医工医药股份有限公司 一种稳定的阿哌沙班口服溶液制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3030272A (en) * 1960-05-26 1962-04-17 Abbott Lab Stable heaparin solution
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
EP0906094B1 (en) 1996-01-02 2003-06-25 Aventis Pharmaceuticals Inc. Substituted n- (aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
GB0108903D0 (en) * 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
FR2863891B1 (fr) * 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
PE20121401A1 (es) * 2009-07-29 2012-10-25 Sanofi Sa Otamixaban para el tratamiento de pacientes con alteracion renal y de edad avanzada con infarto de miocardio sin elevacion del st
KR101852226B1 (ko) 2011-03-29 2018-04-25 사노피 오타믹사반의 벤조산염
MX342324B (es) 2011-03-29 2016-09-23 Sanofi Sa Formulaciones de otamixaban con estabilidad mejorada.

Also Published As

Publication number Publication date
EA025572B1 (ru) 2017-01-30
AU2012234323A1 (en) 2013-10-17
KR20140019818A (ko) 2014-02-17
CA2830962A1 (en) 2012-10-04
CA2830962C (en) 2019-06-18
JP5993933B2 (ja) 2016-09-14
JP2014509621A (ja) 2014-04-21
AR085580A1 (es) 2013-10-09
NZ616180A (en) 2015-10-30
US20120252852A1 (en) 2012-10-04
MX2013011260A (es) 2014-03-27
BR112013024801A2 (pt) 2016-12-20
CO6801755A2 (es) 2013-11-29
SG193932A1 (en) 2013-11-29
ZA201308061B (en) 2015-01-28
CN103561723B (zh) 2016-04-20
CN103561723A (zh) 2014-02-05
MA35050B1 (fr) 2014-04-03
IL228573A (en) 2017-12-31
US20170224668A1 (en) 2017-08-10
US9993464B2 (en) 2018-06-12
UY33975A (es) 2012-10-31
EP2691075A1 (en) 2014-02-05
IL228573A0 (en) 2013-12-31
KR101844623B1 (ko) 2018-04-02
EA201391406A1 (ru) 2014-02-28
US20140018398A1 (en) 2014-01-16
WO2012130819A1 (en) 2012-10-04

Similar Documents

Publication Publication Date Title
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
GEP20207129B (en) Inhibitors of influenza viruses replication
MY149731A (en) Compounds
MX342324B (es) Formulaciones de otamixaban con estabilidad mejorada.
EP2650293A8 (en) [1,2,4]triazolo[4,3-b][1,2,4]triazine compound, preparation method and use thereof
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
GEP201706671B (en) Heterocyclyl compounds as mek inhibitors
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
MX2013005533A (es) Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
IN2014KN00948A (es)
MX2013012588A (es) Inhibidores de cinasa.
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
GEP20166483B (en) Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament
EP2796450A4 (en) 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES
MX2013006768A (es) Moduladores de receptor de glucagon.
MX2013003202A (es) Inhibidores de oxadiazol de la produccion de leucotrienos.
EA201490573A1 (ru) Соединение бензотиазолона
MY161396A (en) Benzoic acid salt of otamixaban
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
PH12016500980A1 (en) Amide derivatives for gpr119 agonist
SA515360076B1 (ar) أملاح من مركب البنزوثيازولون الذي يكون مقاوم لمستقبل أدريني بيتا-2
MY183976A (en) Pharmaceutical composition for oral administration with improved dissolution and/or absorption

Legal Events

Date Code Title Description
FG Grant or registration